MTOR and neoplasm with perivascular epithelioid cell differentiation: Due to aberrant mTOR signaling, mTOR inhibitors have demonstrated efficacy in treating malignant PEComas with the phase II AMPECT trial showing median OS of 40.8 months and progression-free survival (PFS) of 10.6 months (67).